News

ELISA is the method recommended by national pharmacopoeias for detecting residual host cell proteins (HCP) in biological products, capable of quantifying total HCP content. However, ELISA has limitations in distinguishing HCP types and their abundance, necessitating complementary detection methods to address these shortcomings. Each detection technique possesses distinct advantages and disadvantages. In practical applications, methods should be selected and combined based on factors such as experimental objectives, sample characteristics, required accuracy, and operational convenience to achieve more comprehensive and precise detection results.

Furthermore, the United States Pharmacopeia USP<1132> and the European Pharmacopoeia EP 2.6.34. HOST-CELL PROTEIN ASSAYS explicitly state that different ELISA kits are recommended for HCP detection at various stages of product development. They categorise HCP detection methods into three classes: commercial kits, product/process-specific methods and platform-based approaches.

Upon obtaining the antigen and polyclonal antibodies, we can commence the development of the ELISA method. The development process is typically divided into five stages, enabling progression from raw material screening through method establishment to final large-scale production.

2.1 Raw material Related

Preparation and screening of raw materials, including antibodies and other reagents. Antibodies targeting HCPs may sometimes involve antibody pools, where multiple animal immunisation strategies are employed during antibody production, ultimately yielding several HCP antibodies. In such cases, the antibodies require combination screening. Comprehensive evaluation based on antibody coverage, titre, and preliminary ELISA performance is conducted to select the most effective combination for subsequent development. Prepare different types of dilution buffers for diluting and preserving antigens/antibodies. Determine the optimal coating buffer through experimentation to enhance antigen/antibody binding efficiency on solid-phase carriers. Select appropriate blocking solutions to reduce non-specific binding and improve signal-to-background ratios.

2.2 Methodology Establishment

The fundamental operational procedures and conditions for ELISA form the basis of the preliminary methodology. Determine the optimal coating concentration, duration and temperature to ensure uniform distribution of antigen/antibody on the solid-phase carrier. Optimise the number of washes and washing buffers to remove unbound substances and minimise non-specific interference. Determine the optimal incubation time, temperature, and shaking conditions to ensure thorough antigen/antibody binding. Optimise the colour development time and choice of stop solution to guarantee the stability and reproducibility of the colour reaction. Select an appropriate microplate reader and reading wavelength to ensure data accuracy and reliability.

2.3 Methodology Verification

Whether the established methodology meets the anticipated performance requirements. The specificity of the antigen/antibody is verified through cross-reactivity experiments to ensure no cross-reactions occur. The method's limit of detection (LOD) and limit of quantification (LOQ) were determined using the standard curve method. The linear range was validated through multi-point dilution experiments. Precision was verified via repeatability and reproducibility studies. Accuracy was assessed through recovery experiments. Kit stability was confirmed by prolonged storage experiments.

2.4 Methodolgy Confirmation

The applicability and reliability of the methodology in practical application. Verify the applicability of the methodology using samples from different process steps within the project or samples with varying matrices. Validate batch-to-batch consistency through testing with multiple batches of kits. Compare with established standard methods to validate the reliability and consistency of the methodology, promptly identifying and resolving any issues.

2.5 Scale-up Production

Apply validation and confirmation methodologies to large-scale production to ensure product quality and stability. Optimise production process parameters based on small-scale experimental results to achieve mass production. Establish a rigorous quality control system to ensure every batch of products meets quality standards. Maintain detailed records of critical parameters and data throughout the production process to ensure traceability. Conduct regular stability testing to guarantee product performance remains consistent throughout its shelf life. Utilise appropriate packaging materials and transport methods to ensure product safety and integrity during transit.

Junyan Bioscitech possesses a mature and comprehensive technological platform, offering bespoke development services for HCP detection across diverse host cell types. Leveraging an efficient antibody development platform and advanced R&D instrumentation, the company delivers end-to-end services spanning HCP antigen characterisation, high-coverage HCP antibody preparation and analysis, analytical method development and validation, through to large-scale kit production. This ensures the development and stable supply of high-quality HCP ELISA detection kits. Our relentless pursuit of technological excellence and rigorous quality control are dedicated to delivering a service experience that is both reassuring and efficient.

- Employing high-resolution LC-MS for comprehensive characterisation of antigens to obtain HCPs identity information.

- Extensive experience in HCP antibody production, employing a combination of multiple strategies to ensure the generation of high-quality antibodies.

- Characterisation of antibodies was performed using the advanced AAE-MS antibody coverage detection platform.

- Complete method validation in accordance with standards such as the Chinese Pharmacopoeia and ICH, meeting requirements for regulatory submission.

- Development and production transfer strictly adhere to the ISO 13485 quality system, with acceptance of customer on-site audits.

To better meet the testing requirements for biological products, accelerate process optimisation, and facilitate safe release, Junyan Bioscitech has independently developed commercially viable high-coverage HCP detection kits. These include the CHO HCP Residue Detection Kit and the E. coli Expression Host HCP Residue Detection Kit. All kits undergo comprehensive methodological validation to ensure stable and reliable performance.